Reported 2 months ago
Morgan Stanley has designated Eli Lilly (LLY) as a 'top pick,' citing its leading growth potential in the market. This recognition follows the company's impressive second-quarter earnings report, which has led to a significant rise in its stock price. Market analysts Josh Lipton and Madison Mills discuss the implications of this upgrade for Eli Lilly's future.
Source: YAHOO